Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1941 Add-on to Metformin and Sitagliptin in T2DM
NCT02452632Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing ASP1941 Group with Placebo Group (2 arms). Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started Jun 2015; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02452632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452632.